ARCHIVES

NIH director; Targets Increases Favor Established Researchers

This article is from The Cancer Letter archive.

Vol. 23 No. 18 | May 9, 1997

Download PDF Visit The Full Archive

Related Articles

ODAC Actions: Large Subset analysis Of CALGB Study Was Basis for BMS Taxol Application

September 24, 1999

Biological Modifiers Journal Objects To NEJ Policy, Says It Will OK Clinical Data Release

April 26, 1985

NCI Awards 41.5 Million for DES Study

February 28, 1975

FDA Opponents Claim Abuses; Agency Doesn’t Attend Hearing

July 28, 1995

Annual Report Finds Decreases In Overall Cancer Rates

December 11, 2009

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

January 27, 2012